We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
+$145M
Cap. Flow
+$168M
Cap. Flow %
33.56%
Top 10 Hldgs %
91.39%
Holding
26
New
3
Increased
6
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
CGEM icon
Cullinan Oncology
CGEM
+$89.4M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$59.3M
3
IMA
ImageneBio Inc
IMA
+$23.3M
4
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$7.96M
5
ONCR
Oncorus, Inc.
ONCR
+$1.9M

Top Sells

Rank Stock Value
1
AMWL icon
American Well
AMWL
+$6.29M
2
KROS icon
Keros Therapeutics
KROS
+$2.12M
3
OVID icon
Ovid Therapeutics
OVID
+$1.93M
4
DTIL icon
Precision BioSciences
DTIL
+$1.88M
5
INZY
Inozyme Pharma
INZY
+$1.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.45B
$91.8M 18.37%
+2,202,407
New +$89.4M
PLRX icon
2
Pliant Therapeutics
PLRX
$71.2M
$91.4M 18.3%
2,324,795
-30,004
-1% -$974K
RPTX
3
DELISTED
Repare Therapeutics
RPTX
$78.6M 15.73%
2,560,703
+28,553
+1% +$970K
RXDX
4
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$52.5M 10.51%
+2,874,032
New +$59.3M
ORTX
5
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$29.4M 5.89%
405,197
+112,078
+38% +$7.96M
ONCR
6
DELISTED
Oncorus, Inc.
ONCR
$24.7M 4.94%
1,771,786
+91,880
+5% +$1.9M
KROS icon
7
Keros Therapeutics
KROS
$223M
$24.6M 4.93%
400,468
-33,384
-8% -$2.12M
IMA
8
ImageneBio Inc
IMA
$60.5M
$23M 4.61%
+67,896
New +$23.3M
LRMR icon
9
Larimar Therapeutics
LRMR
$421M
$22.1M 4.43%
1,515,148
– –
INZY
10
DELISTED
Inozyme Pharma
INZY
$18.4M 3.68%
927,264
-68,132
-7% -$1.5M
FRLN
11
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$17M 3.41%
92,316
+1,578
+2% +$374K
AKUS
12
DELISTED
Akouos Inc
AKUS
$11.9M 2.38%
858,027
-12,870
-1% -$234K
DTIL icon
13
Precision BioSciences
DTIL
$232M
$7.16M 1.43%
23,054
-5,358
-19% -$1.88M
CRVS icon
14
Corvus Pharmaceuticals
CRVS
$1.24B
$2.09M 0.42%
679,132
+188,255
+38% +$680K
GTHX
15
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.2M 0.24%
50,000
-12,000
-19% -$279K
KZR
16
DELISTED
Kezar Life Sciences
KZR
$1.04M 0.21%
17,417
+3,917
+29% +$229K
OVID icon
17
Ovid Therapeutics
OVID
$572M
$995K 0.2%
247,510
-579,750
-70% -$1.93M
GBT
18
DELISTED
Global Blood Therapeutics, Inc.
GBT
$611K 0.12%
15,000
-7,800
-34% -$359K
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$396K 0.08%
4,021
-1,900
-32% -$228K
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$340K 0.07%
3,500
-2,000
-36% -$200K
RARE icon
21
Ultragenyx Pharmaceutical
RARE
$2.59B
$228K 0.05%
2,000
-1,000
-33% -$136K
AMWL icon
22
American Well
AMWL
$200M
– –
-12,418
Closed -$6.29M
BLUE
23
DELISTED
bluebird bio
BLUE
– –
-618
Closed -$346K
DTIL icon
24
CALL
Precision BioSciences
DTIL
$232M
– –
-333
Closed -$8K
XBI icon
25
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-10,000
Closed -$54K
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, CHI Advisors held 26 positions worth $500M, up 41% from $355M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

CHI Advisors deployed $168M of net new capital in Q1 2021, opening 3 new positions and adding to 6 existing holdings. Its largest new stake was Cullinan Oncology: 2,202,407 shares worth $91.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $2.12M trimmed.

  • CHI Advisors's largest Q1 2021 buy was Cullinan Oncology: 2,202,407 shares worth $91.8M.
  • CHI Advisors added most to Orchard Therapeutics plc American Depositary Shares in Q1 2021, an estimated $7.96M increase.
  • CHI Advisors's biggest Q1 2021 reduction was Keros Therapeutics, cutting an estimated $2.12M.
  • CHI Advisors fully exited American Well in Q1 2021, selling an estimated $6.29M.
  • CHI Advisors's ten largest holdings make up 91% of its $500M portfolio in Q1 2021.
  • CHI Advisors opened 3 new positions and closed 5 in Q1 2021.
  • CHI Advisors's portfolio value rose 41% quarter-over-quarter to $500M.

Based on CHI Advisors's 13F filing for Q1 2021, filed 14 May 2021.